首页>
外国专利>
N-substd.-flavone-8-carboxamide derivs. - useful for treating dysuria by removing hindrances to micturition
N-substd.-flavone-8-carboxamide derivs. - useful for treating dysuria by removing hindrances to micturition
展开▼
机译:N-黄酮8-羧酰胺衍生物。 -通过消除排尿障碍来治疗排尿困难
展开▼
页面导航
摘要
著录项
相似文献
摘要
Cpds. of formula (I) and their acid-addn. salts are new. (R1 is H, Me or Et R2 is H, lower alkyl, lower alkoxy, halogen or NO2 R3 is H or lower alkyl k is 0-3 m is 0 or 1 X and Y are H or Me A is NR4R5, N-R6-pyrrolidinyl or N-6-piperidinyl R4 and R5 are lower alkyl or NR4R5 is cyclic amino opt. contg. an O atom R6 is lower alkyl and n is 2 or 3). Cpds. (I) remove hindrances to micturition e.g. in cystitis or prostatitis and so are useful for treating dysuria they have sufficient stability against acids and non-specific esterases for oral admin. Dose is 100-200 mg 3 times daily orally.
展开▼
机译:Cpds。式(I)的通式及其酸加成基。盐是新的。 (R1是H,Me或Et R2是H,低级烷基,低级烷氧基,卤素或NO2 R3是H或低级烷基k是0-3 m是0或1 X和Y是H或Me A是NR4R5,N- R 6-吡咯烷基或N-6-哌啶基R 4和R 5是低级烷基,或者NR 4 R 5是环状氨基(可选),O原子R 6是低级烷基,n是2或3)。 Cpds。 (I)消除排尿障碍,例如在膀胱炎或前列腺炎中,因此可用于治疗排尿困难,它们对酸和非特异性酯酶具有足够的稳定性,可口服。剂量为100-200毫克,每日口服3次。
展开▼